| Autor: |
Bojtor B; Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary., Balla B; Hungarian Research Network SE-ENDOMOLPAT Research Group, 1085 Budapest, Hungary., Vaszilko M; Department of Oro-Maxillofacial Surgery and Stomatology, Semmelweis University, 1085 Budapest, Hungary., Szentpeteri S; Department of Oro-Maxillofacial Surgery and Stomatology, Semmelweis University, 1085 Budapest, Hungary., Putz Z; Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.; Hungarian Research Network SE-ENDOMOLPAT Research Group, 1085 Budapest, Hungary., Kosa JP; Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.; Hungarian Research Network SE-ENDOMOLPAT Research Group, 1085 Budapest, Hungary., Lakatos P; Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.; Hungarian Research Network SE-ENDOMOLPAT Research Group, 1085 Budapest, Hungary. |
| Abstrakt: |
Medication-related osteonecrosis of the jaw (MRONJ) is a rare side effect of antiresorptive drugs that significantly hinders the quality of life of affected patients. The disease develops in the presence of a combination of factors. Important pathogenetic factors include inflammation, inhibition of bone remodeling, or genetic predisposition. Since the first description of this rare side effect in 2003, a growing body of data has suggested a possible role for genetic factors in the disease. Several genes have been suggested to play an important role in the pathogenesis of MRONJ such as SIRT1 , VEGFA , and CYP2C8 . With the development of molecular biology, newer methods such as miRNA and gene expression studies have been introduced in MRONJ, in addition to methods that can examine the base sequence of the DNA. Describing the complex genetic background of MRONJ can help further understand its pathophysiology as well as identify new therapeutic targets to better manage this adverse drug reaction. |
